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Cardiovascular diseases (CVDs) are disorders 
of the heart and blood vessels, and include coronary 
heart disease, cerebrovascular disease, rheumatic 
heart disease and other conditions. Four out of five 
CVD deaths are due to heart attacks and strokes. In-
dividuals at risk of CVD may demonstrate elevated 
blood pressure, glucose, and lipids as well as over-
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weight and obesity. Identifying those at the highest 
risk of CVDs and ensuring they receive appropriate 
treatment can prevent premature deaths. CVDs are 
the number 1 cause of death globally: more people 
die annually from CVDs than from any other cause. 
An estimated 17.5 million people died from CVDs in 
2012, representing 31% of all global deaths. Of these 
deaths, an estimated 7.4 million were due to coronary 
heart disease and 6.7 million were due to stroke. For 
a secondary prevention of cardiovascular disease in 
those with established disease, including diabetes, 
treatment with the following medications is neces-
sary: aspirin, beta-blockers, statins and angiotensin-
converting enzyme (ACE) inhibitors (1).
The renin-angiotensin-aldosteron system 
(RAAS or RAS) is one of the most important regu-
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latory system of cardiovascular and renal functions. 
The renin-angiotensin system blockade exerts po-
tent antiatherosclerotic effects, which are mediated 
by their antihypertensive, anti-inflammatory, anti-
proliferative, and oxidative-stress-lowering prop-
erties. Inhibitors of the system, ACE inhibitors and 
angiotensin receptor (ATR) blockers, are now first-
line treatments for hypertensive target organ dam-
age and progressive renal disease. Their effects are 
greater than expected by their ability to lower blood 
pressure alone. ATR blockers reduce the frequency of 
atrial fibrillation and stroke. Renin-angiotensin sys-
tem blockade delays or avoids the onset of type 2 dia-
betes and prevents cardiovascular and renal events in 
diabetic patients. Thus, blockade of this system will 
remain a cornerstone of our strategies to reduce car-
diovascular risk (2).
Although significant advances have been made 
in the therapeutic blockade of the RAAS using ACE 
inhibitors, ATR blockers and non-selective aldoste-
rone receptor antagonists, there is a clear need for 
both additional blocking strategies and enhance-
ments of current therapeutic approaches (3).
Renin-Angiotensin-Aldosterone System
The RAS is a complex, highly regulated path-
way that is integral in the regulation of blood vol-
ume, electrolyte balance, and arterial blood pres-
sure. It consists of two main enzymes, renin and 
ACE, whose primary purpose is to release angioten-
sin II from its endogenous precursor, angiotensino-
gen (Fig. 1). Angiotensin II is a potent vasoconstric-
tor which affects peripheral resistance, renal func-
tion and cardiovascular structure (4,5).
The history of the discovery of the renin and 
the elucidation of the RAS began in 1898 when the 
existence of a pressor substance present in crude kid-
ney extracts was demonstrated. Later, it was estab-
lished that this specific substance, which had previ-
ously been named renin, was actually an enzyme and 
that the true pressor substance was a peptide formed 
by the catalytic action of renin. In the 1950s, it was 
discovered that angiotensin exists as both an inactive 
decapeptide, angiotensin I, and an active octapep-
tide, angiotensin II and that the conversion of angio-
tensin I to angiotensin II was catalyzed by an enzyme 
distinct from renin (6,7). Angiotensinogen is an α
2
-
globulin with a molecular weight of 58,000-61,000 
which consist of 452 amino acids, is abundant in the 
plasma, and is continually synthesized and secreted 
by the liver. The most important portion of this com-





bond. This bond is cleaved by renin and produces 





tide bond of angiotensin I is then cleaved by ACE to 
produce the octapeptide angiotensin II. Aminopepti-
dase can further convert angiotensin II to the active 
heptapeptide angiotensin III by removing the N-ter-
minal arginine residue (8). 
Renin is a much more specific enzyme than 
ACE that determines the rate of angiotensin II pro-
duction. Its primary function is to cleave the leucine-
valine bond located at residues 10 and 11 of angio-
tensinogen. The stimulation of renin release is con-
trolled very closely by hemodynamic, neurogenic 
and humoral signals (Fig. 2). Active renin secretion 
is regulated principally by 4 interdependent factors: 
a renal baroreceptor mechanism in the afferent ar-
teriole that senses changes in renal perfusion pres-
Fig. 1. Simplified chart-flow of the renin-angiotensin 
pathway
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sure; changes in delivery of NaCl (sensed as chang-
es in Cl- concentration) to the macula densa cells 
of the distal tubule; sympathetic nerve stimulation 
via β
1
-adrenergic receptors, and negative feedback 
by a direct action of angiotensin II on the JG cells 
(9,10).
ACE, also known as kininase II, is a zinc prote-
ase which removes the C-terminal dipeptide to form 
the octapeptide Ang II [Ang-(1-8)], a biologically ac-
tive, potent vasoconstrictor. It is a relatively nonspe-
cific dipeptidyl carboxypeptidase that requires only 
a tripeptide sequence as a substrate. The only struc-
tural feature required by ACE is that the penultimate 
amino acid in the peptide substrate cannot be pro-
line. It is for this reason that angiotensin II, which 
contains a proline in the penultimate position, is not 
further metabolized by ACE. ACE metabolizes a 
number of other peptides, including the vasodilator 
peptides bradykinin and kallidin, to inactive metab-
olites. The lack of specificity and control exhibited 
by ACE results in its involvement in the bradykinin 
pathway (Fig. 3). Thus, functionally, the enzymatic 
actions of ACE potentially result in increased vaso-
constriction and decreased vasodilation (4,11,12).
Angiotensin II is the primary active product of 
the RAAS, which may have significant biological ac-
tivity, particularly in tissues. Angiotensins III and IV 
are formed by the sequential removal of amino ac-
ids from the N-terminus of Angiotensin II by the ac-
tion of aminopeptidases (Fig. 1). They are most likely 
produced in tissues with high levels of aminopepti-
dases A and N, such as brain and kidney tissue. Ang 
III [Ang-(2-8)], a heptapeptide formed by the remov-
al of the first N-terminal amino acid, is present in the 
central nervous system, where it is thought to play an 
important role intonic blood pressure maintenance 
and in hypertension. Ang IV[Ang-(3-8)] is a hexa-
peptide formed by further enzymatic degradation of 
Ang III. Preclinical studies have suggested a coop-
erative effect of Ang IV in Ang II signaling. For in-
stance, it appears that in the brain, Ang IV increas-
es blood pressure by cooperating with Ang II on an-
giotensin II type 1 (AT1)-receptor signaling), because 
its hemodynamic effects require the presence of both 
Ang II and functional AT1 receptors (13).
A link between the plasma renin activity (PRA) 
and the risk of cardiovascular disease has been dem-
onstrated in several epidemiological studies. Due to 
the fact that the renin-angiotensin pathway is central 
to the maintenance of blood volume, arterial blood 
pressure, and electrolyte balance, abnormalities in 
this pathway can contribute to a variety of cardiovas-
cular disorders, for instance, hypertension or con-
gestive heart failure. Abnormally high levels of an-
giotensin II can contribute to hypertension through 
both rapid and slow pressor responses. Additionally, 
high level of angiotensin II can cause cellular hyper-
trophy and increase both afterload and wall tension. 
There are many experimental and clinical studies 
which provided convincing evidence that the RAS 
is capable of stimulating atherosclerosis by trigger-
ing basic reactions which ultimately lead to growth, 
instability, and rupture of atherosclerotic plaques 
(14,15,16,17,18).
The concept of hypertension as primarily a 
consequence of altered hemodynamics has changed. 
Many factors are now implicated in the development 
of hypertensive vascular disease, and the RAAS ap-
Fig. 2. Factors involved in renin release and the effects 
mediated by angiotensin II
Fig. 3. Schematic representation of the bradykinin path-
way and its relationship to ACE and renin-angiotensin 
pathway
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pears to be one of the most significant. Angiotensin 
II, the principal effector peptide of the RAAS, has 
far-reaching effects on vascular structure, growth 
and fibrosis, and is a key regulator of vascular re-
modeling and inflammation. Treatments that block 
the pathologic effects of the RAAS at several points 
have been shown to limit target-organ damage in hy-
pertension and to decrease cardiovascular morbidity 
and mortality. Understanding the molecular and cel-
lular mechanisms that participate in the early devel-
opment of hypertensive vascular disease may lead to 
more targeted treatment and improved outcomes(19).
Overview of Drug Therapy Affecting the Re-
nin-Angiotensin Pathway
Due to the role of angiotensin II in the produc-
tion of the majority of the effects connected with the 
renin-angiotensin pathway, compounds which can 
block either the synthesis of angiotensin II or the 
binding of angiotensin II to its receptor should af-
fect the actions of this pathway. Indeed, enzyme in-
hibitors of both renin and ACE, as well as receptor 
antagonists of angiotensin II have all been shown to 
produce beneficial effects in decreasing the actions 
of angiotensin II. Inhibitors of ACE were the first 
class of compounds to be marketed. This occurred in 
1981 with the FDA approval of captopril, then losar-
tan was approved as the first angiotensin II receptor 
antagonist. 
Thus, the pharmacological inhibition of the 
RAS can be achieved through three different basic 
mechanisms (20):
1. Inhibition of angiotensin I (Ang I) generation 
from angiotensinogen. This can be achieved 
by direct inhibition of renin, an aspartyl pro-
tease that releases the decapeptide Ang I from 
the α-2-globulin angiotensinogen.
2. Inhibition of angiotensin II (Ang II) genera-
tion from angiotensin I. This can be achieved 
through inhibition of ACE, a zinc-dependent 
protease that generates the octapeptide hor-
mone angiotensin II (Ang II) by cleaving 2 
amino acids (histidine and leucine) from Ang 
I. ACE is highly expressed in the kidney and 
pulmonary endothelium.
3. Inhibition of the action of Ang II at the level 
of its receptor(s).
Attempts to develop orally active, bioavailable 
renin inhibitors actually predate the development of 
ACE inhibitors. Research in this area continues to-
day; however one of the main attractions of renin 
inhibitors, specificity, has turned to be a significant 
hurdle to the clinical development of these agents 
(21).
Angiotensin-Converting Enzyme Inhibitors
The list of ACE inhibitors drugs according FDA 
includes: Benazepril (Lotensin), Captopril (Capo-
ten), Enalapril/Enalaprilat (Vasotec), Fosinopril 
(Monopril), Lisinopril (Zestril and Prinivil), Moex-
ipril (Univasc), Perindopril (Aceon), Quinapril (Ac-
cupril), Ramipril (Altace), and Trandolapril (Ma-
vik)(22). These compounds can be divided into three 
groups based on their chemical structure: sulfhy-
dryl-containing inhibitors exemplified by captopril, 
dicarboxylate-containing inhibitors exemplified by 
enalapril and phosphonate-containing inhibitors ex-
emplified by fosinopril. All of these compounds ef-
fectively block the conversion of angiotensin I to an-
giotensin II and have similar therapeutic and phys-
iologic effects. The compounds differ primarily in 
their potency and pharmacokinetic profile(4). Addi-
tionally, the sulfhydryl group in captopril is respon-
sible for certain effects not seen with the other agent. 
Development of Orally Active Direct Renin 
Inhibitors
Renin, a 340-amino acid protease polypep-
tide, is a member of the aspartyl protease superfam-
ily, which includes pepsin, cathepsin D, and chymo-
sin(23). The octapeptide, His-Pro-Phe-Leu-Leu-Val-
Tyr, is the smallest substrate recognized by the en-


















which is found in angiotensinogen. Using this octa-
peptide, Boger and coworkers (21)replaced the labile 
Leu-Leu bond with the stable dipeptide mimic statin-
eand replaced the two С-terminal residues (Val-Tyr) 
with similar hydrophobic aminoacids (Leu-Phe).
The resulting compound, N-isovaleryl-His-
Pro-Phe-His-Sta-Leu-Phe-NH
2
 (aka SCRIP), was the 
first small molecule renin inhibitor that could main-
tain a lowered blood pressure for an extended period 
of time. However, susceptibility to proteolytic cleav-
age limited the therapeutic utility of SCRIP and oth-
er analogous peptides. 
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Structure-activity studies with SCRIP and ad-
ditional changes resulted in the clinical drug candi-
date enalkiren, also known as A-64662 (Fig. 4). The 
histidine residue (His
6
), present in angiotensinogen 
and all previous inhibitors, was thought to be essen-
tial for enzyme recognition and was left unchanged. 
The acylated tyrosine protects the compounds from 
aminopeptidase enzymes and also contributes to en-
zyme active site recognition. The remainder of the 
molecule is dipeptide isostere. The cyclohexylmeth-
ylene and i-butyl side chains are lipophilic and ap-




 of angiotensinnogen. Additionally, the use 
of C-terminal alcohol instead of C-terminal carbox-
ylate protects enalkiren from carboxypeptidase en-
zymes (24,25).
However, enalkiren lacks significant bioavail-
ability due mainly to a lack of lipid solubility. A more 
lipophilic analog, zankiren (A-72517, Fig. 4), demon-
strated increased oral bioavailability and efficacy, but 
alsohas since been withdrawn from clinical trials for 
undisclosed reasons (26). 
Early attempts to develop direct renin inhibi-
tors for the treatment of hypertension and associat-
ed CVDs were hampered by poor oral bioavailabil-
ity, lack of clinical efficacy, short plasma half-lives 
and high cost of synthesis. However, a combination 
of molecular modelling techniques and crystal struc-
ture elucidation led to the development of aliskiren 
(Fig. 4), which will be the first orally effective di-
rect renin inhibitorfor the treatment of hyperten-
sion. Aliskiren is a highly specific inhibitor of hu-
man renin in vitro (27). Aliskiren, the direct renin 
inhibitor which was recently approved for treatment 
of hypertension, represents the most recent class of 
agents that block the RAAS. This compound differs 
from the ACE inhibitors and ATR blockers in that, 
by blocking the catalytic activity of renin at the point 
of activation of the RAAS, it blocks the synthesis of 
all angiotensin peptides and prevents the compensa-
tory increase in renin activity (28).
There were some attempts to develop a potent, 
selective and orally active renin inhibitors based on 
iminopyrimidinones(29), iminotetrahydropyrimidi-
nones (30), 3,4diarylpiperidines(31).
Chymase, a chymotrypsin-like serine prote-
ase that is abundant in secretory granules from mast 
cells, has been identified to be a key enzyme in the lo-
cal RAS that generates angiotensin II (Ang II) inde-
pendent of ACE. The pathophysiological significance 
of alternative Ang II-forming pathways in human 
CVDs remains controversial. Although chymase in-
hibitors, unlike ACE inhibitors and Ang II type 1 re-
ceptor blockers, may only play a small role in the reg-
Fig. 4. Chemical structures of enalkiren, zankiren, and aliskiren
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ulation of the systemic RAS, the possible applications 
of chymase inhibitors as new drugs that inhibit the 
local RAS to prevent CVDs are described in animal 
models. In this review, we discuss the possible appli-
cation of chymase inhibitors as new drugs to inhibit 
the RAS mainly in cardiovascular diseases(32).
Chymase inhibitors could have the advantage of 
being effective even if used after injury. Several oral-
ly active inhibitors, including SUN-C8257, BCEAB, 
NK3201 and TEI-E548 (Fig. 5), are under develop-
ment. Orally active inhibitors of chymase may have a 
place in the treatment of vascular diseases where in-
jury-induced mast cell degranulation contributes to 
the pathology (33).
Sulfhydryl-Containing Inhibitors
The discovery of specific factors in 1965 (bra-
dykinin potentiating factors (BPFs)) which potentiat-
ed the action of bradykinin, was a trigger of the new 
pattern in development ACE inhibitors. The action 
of these factors was subsequently linked to their abil-
ity to the enzymatic degradation of bradykinin. Lat-
er, the BPF was tested on ACE and found to be a po-
tent inhibitor thereof. This led to Vane’s strong inter-
est in ACE and its inhibition as a means of treating 
hypertension (34).
A nonapeptide, SQ 20881 (Fig. 6), isolated from 
the original BPFs had the greatest in vivo potency in 
inhibiting ACE and was shown to consistently low-
er blood pressure in patients with essential hyperten-
sion. It also exerted beneficial effects in patients with 
heart failure; however, due to its peptide nature and 
lack of oral activity, teprotide had limited activity in 
the therapeutic treatment of these diseases (35,36).
In further research, SQ 20881 and other pep-
tide analogs, were used to provide an enhanced un-
derstanding of the enzymatic properties of ACE and 
developed a hypothetical model of the enzyme ac-
tive site (37,38,39). Using the structure of carboxy-
peptidase A (Fig. 7) -a zinc-containing exopeptidase 
- were elucidated the binding of a substrate to car-
boxypeptidase A (Fig. 7, part A), and the binding of 
Fig. 5. Chemical structures of some chymase inhibitors
Fig. 6. Chemical structure of SQ 20881.
Fig. 7. Modeling of substrate binding to carboxypeptidase A (A) and ACE (B)
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substrates to ACE, which involves three major inter-
actions (Fig. 7, part B) (40). 
The role of D-2-benzylsuccinic acid as an ex-
tremely potent inhibitor of carboxypeptidase A was 
later found (37,38,39). Binding to carboxypeptidase 
A (Fig. 8, part A) it is very similar to that seen for sub-
strates with the exception that the zinc ion binds to a 
carboxylate group instead of the labile peptide bond. 
This hypothetical model of ACE resulted in the syn-
thesis and evaluation of a series of succinic acid de-
rivatives (Fig. 8, part B) (41).
Later it discovered that proline was the C-ter-
minal amino acid in SQ 20881 as well as in other po-
tent, inhibitory snake venom peptides. Thus, this 
scaffold was included in the structure of the new-
ly designed inhibitor. Using these tools the first ‘de-
signed’ inhibitor, succinyl-L-proline was synthesized 
(Fig. 9). It seemed to be a specific inhibitor of ACE 
although of very low potency. Subsequent structural 
modifications of this convinced the researchers that 
it was the right track (42).
Therefore, further structural modifications of 
succinyl-proline, which included the replacement of 
the carboxyl group of the succinyl moiety with other 
atoms or group of atoms that could also function as 
zinc ligands. Among those tested early on were the 
hydroxamic acid group and the sulfhydryl group, 
which eventually led to captopril. All the structural 
modifications that were studied with captopril 
confirmed that this molecule was interacting very 
specifically with the active site of ACE. 
Practically every functional group in captopril 
is important in the overall inhibitory activity by pro-
viding strong and specific interactions with the dif-
ferent ‘pockets’ of this active site. Because of its sulf-
hydryl group, captopril can show inhibitory activi-
ty towards other zinc metalloproteases, but these ac-
tivities are several orders of magnitude weaker than 
that seen with ACE. The assumption that the sulfhy-
dryl group functions as a ligand of the active site zinc 
has been shown to be correct by studying the three-
dimensional structure of a specially designed thiol-
containing inhibitor with the metalloprotease ther-
molysin using X-ray crystallography (42).
Of course, all this potency and specificity would 
have been of little value without good oral absorp-
tion. Fortunately, captopril has one-fifth of the mo-
lecular size of teprotide and, strictly speaking, has no 
Fig. 8. Molecular modeling of inhibitor binding D-2-benzylsuccinic acid to carboxypeptidase (A) and succinic acid deriv-
atives (B) to ACE 
Fig. 9. Chemical structures of compounds designed in the 
development of captopril.
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peptide bonds. It was therefore no surprise that its 
antihypertensive activity was equal or better by the 
oral route than by the parenteral route(42).
Since the advent of captopril, several other ACE 
inhibitors have been developed and introduced into 
clinical practice; each of these compounds has its 
own distinct chemical and pharmacological prop-
erties. Zofenopril (Fig. 10) is an ACE inhibitor with 
unique pharmacodynamic and pharmacokinetic 
properties (43).
Dicarboxylate-Containing Inhibitors 
The most common adverse effects of capto-
pril, skin rash and taste disturbance, are the same as 
those caused by mercapto-containing penicillamine. 
Therefore a group of researchers aimed at finding po-
tent, selective ACE inhibitors that wouldn’t contain 
a mercapto (SH) function and would have a weak-
er chelating function. Compounds having the gen-
eral structure shown below were designed to meet 
this objective (Fig. 11). All these compounds have the 
C-terminal (A) and penultimate (B) amino acids are 
retained but the third amino acid is isosterically re-
placed by a substituted N-carboxymethyl group (C) 
(44).
Enalapril is an ACE inhibitor, known as the 
dicarboxylate-containing ACE inhibitor, normally 
used in the treatment of hypertension and chronic 
heart failure, was developed and patented by Merck 
& Co., Inc (Whitehouse Station, NJ, USA) under the 
trade names Renitec and Vasotec(45). In comparing 
the activity of captopril and enalaprilat, it was found 
that enalaprilat was approximately 10-fold more po-
tent than captopril.
As shown in Figure 12, enalaprilat possess-
es a tetrahedral carbon in place of the labile peptide 
bond. The secondary amine, the carboxylic acid and 
phenylethyl groups all contribute to the overall bind-
ing of the compound to ACE. The secondary amine 
is located at the same position as the labile amide ni-
trogen, the ionized carboxylic acid can form an ionic 
bond with the zinc atom, and the phenylethyl group 
mimics the hydrophobic side chain of the Phe amino 
acid which is present in angiotensin I.
Enalapril is a prodrug that is converted by 
deesterification to converting enzyme inhibitor, enal-
aprilat, with effects similar to those of captopril (Fig. 
13). Enalapril itself is available only for intravenous 
use, primarily for hypertensive emergencies(46,47).
Lisinopril (lye-SIN-o-pril) is simply the lysine 
analog of enalapril. Unlike enalapril, lisinopril itself 
is active with a long duration of action. Historical-
ly, lisinopril was the third ACE inhibitor, after cap-
topril and enalapril, and was introduced into therapy 
in the early 1990s. Lisinopril has a number of prop-
erties that distinguish it from other ACE inhibitors: 
it is hydrophilic, has long half-life and tissue pene-
tration and is not metabolized by the liver. Lisinopril 
is the only ACE inhibitor that exhibits a linear dose-
response curve. Lisinopril, along with captopril, are 
currently the only two ACE inhibitors which are not 
prodrugs(48).
Other dicarboxylate inhibitors which have been 
approved for various therapeutic indications are pre-
sented in Table 1; however, spirapril has never been 
marketed. 
Studies of indoline analogs of captopril indicat-
ed that a hydrophobic pocket similar to that seen in 
carboxypeptidase A was also present in ACE. This 
led to a modification (Fig. 14) of Ondetti and Cush-
man’s original model and the development of inhib-
itors which contained larger hydrophobic ring sys-
tems (49). Even though this modified model was pro-
posed for captopril analogs, it is readily adaptable 
to include enalaprilat analogs. In general, the var-
ied ring systems seen in benazepril, moexipril, per-
Fig. 10. Chemical stuctures of zofenopril and zofenoprilat
Fig. 11. General structure of compounds that were de-
signed to overcome the most common adverse effects of 
captopril
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indopril, quinapril, ramipril, spirapril, and trandol-
april provide enhanced binding and potency. They 
also lead to differences in absorption, plasma protein 
binding, elimination, onset of action, duration of ac-
tion and dosing among the drugs. 
A series of novel diethyl 2,6-dimethyl-1,4-di-
hydropyridine-3,5-dicarboxylate embedded triazole 
and Mannich bases were synthesized, and evaluated 
for their ACE inhibitory activity(50).
Phosphonate-Containing Inhibitors
The quest for ACE inhibitors devoid of the sulf-
hydryl group also led to the evaluation of phospho-
rous containing compounds, on the basis of the no-
tion that phosphinic acid is bioisosterically equiva-
lent to sulfhydryl and carboxylate groups in terms of 
Zn2+ chelation (Fig. 15) (51). Additionally, this com-
Fig. 12. Schematic presentation of enalaprilat similarity with the transition state of angiotensin I hydrolysis by ACE
Fig. 13. Scheme of enalapril bioactivation
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pound is capable of forming the ionic, hydrogen, and 
hydrophobic bonds similar to those seen with enala-
pril and other dicarboxylate analogs. 
This led to the development of fosinopril as a 
prodrug that is hydrolyzed by liver enzymes to the 
bioactive fosinoprilat (Fig. 16). This сompound was 
more potent than captopril but less potent than enal-
aprilat. The above-mentioned differences in the spac-
ing of the phosphinic acid and phenyl groups may be 
responsible for this latter difference in potency.
Similar to the dicarboxylates, fosinoprilat was 
too hydrophilic and exhibited poor oral activity. The 
prodrug fosinopril contains an (acyloxy)alkyl group 
which allows for better lipid solubility and improved 
liability (52).
A series of phosphonate analogues related to 
perindopril and ramipril were prepared and tested to 
estimate their ability to inhibit ACE. These new syn-
thesized compounds were active ACE inhibitors with 
a promising activity (53).
The structural characteristics for ACE inhibito-
ry activity are given in Table 2. ACE is a stereoselec-
tive drug target. Since currently approved ACE in-
hibitors act as either di- or tripeptide substrate ana-
logs, they must contain a stereochemistry that is con-
sistent with the L-amino acids present in the natural 
substrates. This was established very early in the de-
Fig. 14. Schematic presentation of the main scaffolds of 
ACE inhibitors, enalaprilat analogs
Fig. 15. Model of binding of phosphinate analogs to ACE
Fig. 16. Scheme of fosinopril bioactivation
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velopment of ACE inhibitors when compounds with 
carboxyl-terminal D-amino acids were discovered to 
be very poor inhibitors (6). Later work by Patchett et 
al. (44) reinforced this idea. They reported a 100- to 
1000-fold loss in inhibitor activity whenever the con-
figuration of either the carboxylate or the R
1
 substit-
uent (Table 1) was altered. The S,S,S configuration 
seen in enalapril and other dicarboxylate inhibitors 
meets the above stated criteria and provides for opti-
mum enzyme inhibition (44).
To correlate the molecular properties of the 
most of ACE inhibitors (captopril, enalapril, perin-
dopril, lisinopril, ramipril, trandolapril, quinapril, 
fosinopril, benazepril, and cilazapril) and some of 
their active metabolites (enalaprilat, perindoprilat, 
ramiprilat, trandolaprilat, quinaprilat, fosinoprilat, 
benazeprilat, and cilazaprilat) computational chemi-
cal methods have been used. The computed pK
a
 val-
ues correlate well with the available experimental 
values. In the dicarboxylic ACE inhibitors, the car-
boxyalkyl carboxylate group of the ACE inhibitors 
studied is more acidic than the C-terminal carbox-
ylate. However, at physiological pH=7.4 both car-
boxyl groups of ACE inhibitors are completely ion-
ized and the dicarboxyl-containing ACE inhibitors 
behave as strong acids. The available experimental 
partition coefficients of these ACE inhibitors inves-
tigated are well reproduced by the neural network-
based ALOGPs and the fragment-based KoWWiN 
methods.
All parent drugs (and prodrugs), with the ex-
ception of fosinopril, are compounds with low lipo-
philicity. Calculated pK
a
, lipophilicity, solubility, ab-
sorption, and polar surface area of the most effec-
tive ACE inhibitors for the prevention of myocardi-
al infarction, perindopril and ramipril, were found 
similar. Therefore, it is probable that the experimen-
tally observed differences in the survival benefits in 
the first year after acute myocardial infarction in pa-
tients 65 years of age or older correlate closely to the 
physicochemical and pharmacokinetic characteris-
tics of the specific ACE inhibitor that is used (54).
Thus, a chemical overview of the compounds 
that influence the RAS and show cardiovascular ef-
fects, in particular ACE inhibitors, has been done in 
this article. Different approaches to the rational de-
sign of the new modern antihypertensive drugs have 
been discussed and the essential structural features 
of ACE inhibitiors have been shown based upon the 
SAR analysis data. Other classes of medicines that 
act on RAS, namely angiotensin II receptor antago-

























a. !e N-ring must contain a carboxylic acid to mimic the C-terminal of ACE substrates.
b. Large hydrophobic heterocyclic rings in the N-ring increase potency and alter pharmacokinetic parameters. 
c. Groups A,B or C can serve as zinc binding groups
d. !e sul"ydryl group shows superior binding to zinc (Phe in carboxylate and phosphinic acidside chain compensates for sul"ydryl 
group).
e. Sul"ydryl-containing compounds produce high, incidence of skin rash and taste disturbances.
f. Sul"ydryl-containing compounds can form disul#des which may shorten duration of action.
g. Binding to zinc through either a carboxylate or phosphinate mimics the peptide hydrolysis transition state.
h. Esteri#caion of the carboxylate or phosphinate produces an orally bioavailable prodrug. 
i. X is usually methyl to mimic the side chain of alanine. Within the dicarboxylate series, when X equals n-butylamine (lysine side 
chain), this produces a compound which is orally active without being a prodrug.
j. Optimum activity occurs when stereochemistry of inhibitor is consistent with L-amino acid stereochemistry
Table 2. Structure-activity relationship of ACE inhibitors
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